Financial toxicity correlated with worse psychological well-being among breast cancer surgical patients
Financial toxicity among breast cancer patients is independently associated with worse psychological well-being following a mastectomy or lumpectomy operation. However, even small improvements in financial pressure associated with treatment-related costs can lead to better mental well-being and higher patient satisfaction with breast reconstruction, according to an article in press published on the website of the
Journal of the American College of Surgeons ahead of print.
Women undergoing breast cancer surgery are vulnerable to financial stress due to the expensive and extended duration of treatment. High out-of-pocket costs can take a major toll on a patient s health, leading to financial toxicity (the harm or stress a person experiences due to the unaffordability of his or her medical care).
Ziopharm Comments on Delay of WaterMill’s Stated Consent Deadline
Ziopharm Recommends Shareholders Return the
GREEN Consent Revocation Card
BOSTON, Dec. 11, 2020 (GLOBE NEWSWIRE) Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today issued a statement in connection with the consent solicitation (the “Consent Solicitation”) initiated by WaterMill Asset Management Corp., Mr. Robert W. Postma and certain other individuals (collectively, “WaterMill”) following the delay of the original December 11 deadline set by WaterMill for Ziopharm shareholders to deliver written consents in support of the Consent Solicitation. Ziopharm continues to strongly recommend shareholders sign and return the Company’s
GREEN Consent Revocation Card.
Skip to main content
Frontline workers at some Houston hospitals in poor areas left out of the first round of vaccines
FacebookTwitterEmail 14
1of14Tanna Ingraham, right, is hugged by medical student Pauleth Tenorio, left, inside her room at United Memorial Medical Center, on Friday, Dec. 11, 2020, in Houston. Ingraham, who is a registered nurse and works at UMMC s COVID Unit, has contracted the virus for the second time in six months. As thousands of health care workers at Houston s largest hospitals will be first in line to receive the new COVID-19 vaccine in the coming days, those at smaller institutions, including UMMC will get none.Godofredo A. Vásquez/Staff photographerShow MoreShow Less
s
Independent financial analysts widely recognize this progress:
“ZIOP continues to make progress with respect to the company-sponsored TCR-T program, the Controlled IL-12 program, and the Sleeping Beauty CAR-T program.”
2
“By unlocking the potential of its Sleeping Beauty technology, the Company is poised to deliver a leap forward in the personalization of cancer therapy.”
3
“We think that the company continues to make forward progress across its various platforms (TCR-T, CAR-T, and controlled IL-12).ZIOP has executed well over 2020 in curating immune receptors from its own libraries and it is moving forward its wholly owned program.”
4
The Company continues to urge shareholders to support Ziopharm’s continued progress and protect the value of their investment by signing and returning the